Catalyst Calendar
Scope

Tue, Jun 30, 2026

1 updates
JAGX
9:00 AM

Presentation at ESPGHAN 2026 Describes Additional Groundbreaking Results of Evaluation of Jaguar Health's Crofelemer as Adjunctive Oral Therapy for the Treatment of Pediatric Intestinal Failure (IF)

Company remains sharply focused on its ongoing global development program for crofelemer for rare IF diseases Near-term milestones for IF program buttressed by continuing groundbreaking results of study, which demonstrate reduction of parenteral support normalized to body weight of up to 48% in

Presentation / AbstractESPGHAN e-poster presentation Sat, Jun 27, 2026jaguar.health

Thu, Jun 25, 2026

1 updates
JAGX
9:00 AM

Jaguar Health Announces Conversion of Series O Convertible Preferred Stock Issued as Recent One-time Stock Dividend

Company remains sharply focused on its ongoing global development program for crofelemer for rare intestinal failure diseases Reminder: Two crofelemer presentations in pediatric intestinal failure patients with microvillus inclusion disease (MVID) and short bowel syndrome (SBS-IF) to be conducted

Presentation / Abstract • Phase 2ESPGHAN presentations Mon, Jun 1, 2026jaguar.health

Tue, Jun 23, 2026

1 updates

Mon, Jun 22, 2026

1 updates
JAGX
9:00 AM

Jaguar Health Announces Plan to Explore Strategic Alternatives Aligned with Targeted NDA Filing for Rare Disease Intestinal Failure Program

Reminder: Lisa Conte, Jaguar's founder & CEO, to present on June 24, 2026 at the Life Sciences Virtual Investor Forum to provide updates on company's crofelemer development program for rare intestinal failure diseases; click here to register SAN FRANCISCO, CA / ACCESS Newswire / June 22, 2026 /

Presentation / AbstractESPGHAN late-breaking abstract presentation Wed, Jun 24, 2026jaguar.health

Thu, Jun 18, 2026

1 updates

Fri, Jun 12, 2026

1 updates
JAGX
9:00 AM

Jaguar Health Presenting June 24, 2026 at the Life Sciences Virtual Investor Forum to Provide Updates on Company's Crofelemer Development Program for Rare Intestinal Failure Diseases

Click here to register for event To access the replay of the June 10, 2026 presentation by Lisa Conte, Jaguar's founder, president & CEO, at the Emerging Growth Conference, click here Reminder: Two crofelemer presentations in pediatric intestinal failure patients with microvillus inclusion disease

Presentation / AbstractESPGHAN abstract release Wed, Jun 24, 2026jaguar.health

Mon, Jun 8, 2026

1 updates

Thu, May 28, 2026

1 updates
JAGX
10:00 AM

Jaguar Health Research in Ethnobotanical Medicine Helps Advance Crofelemer Development for Genetically Defined Rare Congenital Gastrointestinal Disorders

Crofelemer delayed-release tablets are Jaguar's FDA-approved prescription drug under botanical guidance ("botanical drug") derived from the Croton lechleri tree. Crofelemer, in a novel liquid formulation, is being developed as the potential first oral adjunctive therapy for Intestinal Failure (IF)

Presentation / AbstractESPGHAN late-breaking abstracts Thu, May 28, 2026jaguar.health

Wed, May 27, 2026

1 updates
JAGX
9:00 AM

Jaguar Health Compliant with Nasdaq Bid Price Rule

JAGX's securities continue to be listed and traded on Nasdaq SAN FRANCISCO, CA / ACCESS Newswire / May 27, 2026 / Jaguar Health, Inc. ( NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that on May 26, 2026, the Company received formal notice from The Nasdaq Stock Market LLC ("Nasdaq") that

jaguar.health

Wed, May 20, 2026

2 updates
JAGX
4:40 PM

Jaguar Health Reports First Quarter 2026 Financials

Net revenue increased 816% in Q1 2026 vs. Q1 2025, and increased 527% in Q1 2026 vs. Q4 2025, buoyed by license of U.S. commercial rights for Mytesi ® and Canalevia ® -CA1 Company continues its focus on crofelemer development efforts for rare-disease intestinal failure indications; two crofelemer

Presentation / AbstractESPGHAN abstract release Mon, Jun 1, 2026jaguar.health
JAGX
9:00 AM

Jaguar Health to Hold Investor Webcast May 26 Regarding Q1 2026 Financials & Corporate Updates; Jaguar CEO Lisa Conte Presenting May 28 at Lytham Partners Spring 2026 Investor Conference

Click here to register for Jaguar's May 26 webcast; Click here to register for May 28 virtual presentation at Lytham Partners Conference Company plans to file its Earnings Report on May 20, 2026 on Form 10-Q for the quarter ended March 31, 2026 SAN FRANCISCO, CA / ACCESS Newswire / May 20, 2026 /

jaguar.health

Tue, May 19, 2026

1 updates
JAGX
9:00 AM

Jaguar Health Announces Active Treatment Only Continuation of Pivotal Multicenter Clinical Trial in Pediatric Patients with Microvillus Inclusion Disease (MVID) to Support a New Drug Application (NDA) for Liquid Oral Crofelemer

First MVID patient enters the active treatment only extension phase after completion of randomized double-blind crossover period to evaluate longer-term safety and efficacy with liquid oral crofelemer as adjunctive treatment for MVID, an ultrarare pediatric disease with a lethal natural history and

Presentation / AbstractESPGHAN presentation Mon, Jun 1, 2026jaguar.health

Fri, May 8, 2026

1 updates
JAGX
9:00 AM

Jaguar Health Regains Compliance with Nasdaq's Publicly Held Shares Requirement and Receives Additional Extension, Until May 18, 2026, to Demonstrate Compliance with Nasdaq's Bid Price Rule

SAN FRANCISCO, CA / ACCESS Newswire / May 8, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today provided an update on the status of the Company's listing on The Nasdaq Stock Market ("Nasdaq"). On May 6, 2026, Jaguar received a decision letter from the Nasdaq Hearings Panel

jaguar.health

Wed, May 6, 2026

1 updates

Mon, May 4, 2026

1 updates

Wed, Apr 29, 2026

1 updates

Mon, Apr 27, 2026

1 updates

Fri, Apr 24, 2026

1 updates
JAGX
8:30 AM

Jaguar Health Announces Acceptance of two Late-Breaking Abstracts for Liquid Oral Crofelemer Treatment of Intestinal Failure in Pediatric Patients at the European Society for Pediatric Gastroenterology, Hepatology & Nutrition (ESPGHAN)

Intestinal Failure (IF) occurs in patients with an ultrarare congenital enteropathy due to microvillus inclusion disease (MVID) and/or short bowel syndrome (SBS) Jaguar has received orphan drug designations for MVID & SBS in the US and EU Jaguar has also completed enrollment of pediatric MVID

Presentation / Abstractjaguar.health

Mon, Apr 20, 2026

1 updates